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Summary
Accumulating evidence indicates an important role for serine phosphorylation of IRS-1 in the regulation of insulin action.
Recent studies suggest that Rho-kinase (ROK) is a mediator of insulin signaling, via interaction with IRS-1. Here we
show that insulin stimulation of glucose transport is impaired when ROK is chemically or biologically inhibited in cultured
adipocytes and myotubes and in isolated soleus muscle ex vivo. Inactivation of ROK also reduces insulin-stimulated
IRS-1 tyrosine phosphorylation and PI3K activity. Moreover, inhibition of ROK activity in mice causes insulin resistance by
reducing insulin-stimulated glucose uptake in skeletal muscle in vivo. Mass spectrometry analysis identifies IRS-1 Ser632/
635 as substrates of ROK in vitro, and mutation of these sites inhibits insulin signaling. These results strongly suggest
that ROK regulates insulin-stimulated glucose transport in vitro and in vivo. Thus, ROK is an important regulator of insulin
signaling and glucose metabolism.Introduction
Insulin action is mediated by a cascade of tyrosyl phosphoryla-
tion events, initiated by binding of insulin to its receptor (White,
2002). Binding increases the kinase activity of the insulin re-
ceptor (IR), which then phosphorylates insulin receptor sub-
strate (IRS) proteins on multiple tyrosine residues. Phosphoty-
rosyl residues on IRS proteins act as docking sites for SH2
domains containing proteins, including the p85 regulatory sub-
unit of PI3K. Upon binding to IRS proteins, PI3K is activated
and promotes glucose uptake into skeletal muscle and adipose
tissue by stimulating translocation of the glucose transporter 4
(Glut4) from intracellular stores to the cell surface. Defects in
glucose transport result in insulin resistance, which is a major
factor in the development of type 2 diabetes (DeFronzo, 1997).
The molecular basis for this insulin resistance remains unclear.
Evidence is accumulating that serine phosphorylation of
IRS-1 plays an important role in the regulation of insulin action
(Zick, 2001). IRS-1 contains more than 100 potential serine
phosphorylation sites (White, 1997), which are recognized by
many kinases, including JNK (Aguirre et al., 2000), PKCs
(Greene et al., 2004), mTOR (Ozes et al., 2001), MAPK (De Fea
and Roth, 1997), and AMPK (Jakobsen et al., 2001). Modifica-
tion of IRS-1 by serine phosphorylation may be a mechanism
by which the phosphorylation of specific tyrosine residues is
altered, thereby regulating the downstream signaling eventsCELL METABOLISM : AUGUST 2005 · VOL. 2 · COPYRIGHT © 2005 ELS(Zick, 2001). Recent findings demonstrate that serine phos-
phorylation of IRS-1 protein in response to insulin may either
enhance or terminate insulin signaling depending on the serine
residue phosphorylated (Zick, 2001). It is likely that IRS-1 func-
tion is regulated in several ways, including the interaction
between specific serine kinases and IRS-1, regulation of the
associated kinase activities, and the selection of specific phos-
phorylation sites. Therefore, the identification of the serine ki-
nases that phosphorylate specific serine residues on IRS-1 is
important in understanding the mechanism for dysregulation of
insulin action in altered metabolic states.
Some studies suggest that ROK, one of the major Rho tar-
gets, is likely to be an important mediator in insulin signaling
via a direct interaction with IRS-1 (Begum et al., 2002; Farah et
al., 1998). ROK has been shown to negatively regulate insulin
signaling in some cell lines by increasing IRS-1 serine phos-
phorylation (Begum et al., 2002; Sordella et al., 2002). Since
there is no evidence that ROK phosphorylates IRS-1 directly,
how ROK mediates its effects on insulin signaling via serine
phosphorylation of IRS-1 is unclear. Furthermore, the molecu-
lar mechanism(s) by which ROK regulates insulin signaling and
glucose metabolism have not been identified.
In this study, we investigated the function of ROK in IRS-1-
mediated signaling by inhibiting its activity in adipocyte and
muscle cell lines, as well as in whole muscles studied ex vivo.
We also sought to determine the contribution of ROK to in vivoEVIER INC. DOI 10.1016/j.cmet.2005.06.011 119
A R T I C L Eglucose homeostasis in mice. Here we show that ROK regu-
lates insulin-stimulated glucose transport via PI3K activation,
which can be positively regulated by IRS-1 serine phosphoryla-
tion. We further demonstrate that ROK plays an important role
in regulating whole-body glucose disposal and glucose uptake
in muscle in vivo.
Results
Inhibition of ROK activity impairs insulin stimulation
of glucose transport in 3T3-L1 adipocytes
and L6 myotubes
Studies suggest that ROK may play an important role in insulin
signaling pathway via a direct interaction with IRS-1 (Begum et
al., 2002; Farah et al., 1998). However, the role of ROK in insu-
lin-stimulated glucose metabolism is unknown. In order to de-
termine whether ROK can regulate insulin-stimulated glucose
transport, we measured 2-deoxyglucose uptake in adipocytes
and myotubes transduced with DN-ROK. DN-ROK lacks the
kinase domain and has a mutant Rho binding domain. This
dominant-negative allele interacts with the catalytic region ofFigure 1. Effects of ROK inhibition on insulin-stimulated glucose transport in 3T3-L1 adipocytes and L6 myotubes
A) Effects of DN-ROK on insulin-stimulated glucose transport in 3T3-L1 adipocytes and L6 myotubes. Cells were transduced with adenoviruses encoding β-Gal or
DN-ROK. ROK was visualized by immunoblotting with a ROK antibody or a myc-tagged antibody. Cells were starved and then stimulated with insulin (1.0, or 100 nM)
for 30 min. [3H]-2-deoxy-D-glucose uptake was measured.
B) Inhibition of insulin-stimulated glucose transport by knockdown of endogenous ROK expression in 3T3-L1 adipocytes. Cells were transfected with ROK-siRNA or
control siRNA (12.5 nmol of siRNA oligonucleotides/5 × 106 cells) by electroporation. ROK was visualized by immunoblotting with a ROK antibody. Cells were starved
and then stimulated with insulin (100 nM) for 30 min. [3H]-2-deoxy-D-glucose uptake was measured.
C) Effects of DN-ROK on insulin-stimulated Glut4 translocation in 3T3-L1 adipocytes overexpressing Glut4. Cells were transduced with adenoviruses encoding β-Gal
or DN-ROK. Cells were starved and then stimulated with insulin (100 nM) for 20 min. Cell surface bound myc-Glut4 was detected using a myc-tag antibody. Glut4
translocation is shown as a percentage of β-Gal-transduced cells.
Data are mean ± SEM and are representative of three independent experiments. #p < 0.01 versus no virus or β-Gal with insulin. †p < 0.01 versus control. ‡p < 0.01
versus the corresponding condition with insulin. ¶p < 0.01 versus β-Gal without insulin.120the endogenous ROK and blocks its activity independent of
GTP-Rho (Amano et al., 1997, 1998). Western blotting of cell
lysates showed a strong signal of w55 kDa in 3T3-L1 adipo-
cytes and L6 myotubes transduced with recombinant adenovi-
rus encoding DN-ROK. No signal was detected in control cells
transduced with β-Gal adenovirus. DN-ROK had no effect on
the expression level of endogenous ROK in adipocytes and
myotubes (Figure 1A).
Insulin (100 nM) increased 2-deoxyglucose uptakew11-fold
in control 3T3-L1 adipocytes. Expression of β-Gal in adipo-
cytes did not significantly change basal or insulin-stimulated
glucose transport. In contrast, DN-ROK expression decreased
insulin-stimulated glucose transport by w50% (Figure 1A).
Consistent with this, DN-ROK significantly reduced insulin
stimulation of glucose transport at a physiological dose of in-
sulin in these cells (Figure 1A).
Insulin also increased glucose transport w2-fold in control
myotubes and myotubes transduced with β-Gal. In cells ex-
pressing DN-ROK, glucose transport was not stimulated in re-
sponse to insulin and was significantly decreased compared
with insulin-stimulated values in control cells (Figure 1A).CELL METABOLISM : AUGUST 2005
Rho-kinase as a positive mediator of insulin actionTo further investigate the effects of ROK on insulin-stim-
ulated glucose transport in 3T3-L1 adipocytes, we used ROK
siRNA to suppress the expression of endogenous ROK. En-
dogenous ROK expression was reduced byw55% after trans-
fection of siRNA ROK (Figure 1B). Moreover, suppression of
ROK expression significantly caused a >33% decrease in insu-
lin-stimulated glucose transport in 3T3-L1 adipocytes (Figure
1B). These data strongly imply that activation of ROK is re-
quired for maximal insulin-stimulated glucose transport in adi-
pocytes and muscle cells.
To determine whether decreased glucose transport by ROK
inhibition was due to translocation of Glut4 to the plasma
membrane, we measured the amount of Glut4 on the cell sur-
face in 3T3-L1 adipocytes overexpressing c-myc-tagged Glut4.
As expected, insulin increased the amount of myc-Glut4 on the
cell surface w1.7-fold over basal levels in 3T3-L1 myc-Glut4
adipocytes transduced with β-Gal. This effect was inhibited by
expression of DN-ROK (Figure 1C). These data indicate that
reduction of insulin-induced glucose transport by ROK inhibi-
tion is due to decreased Glut4 translocation to the plasma
membrane.
We also employed a chemical inhibitor of ROK (Y-27632) to
examine the ROK’s effects on insulin-induced glucose uptake
in 3T3-L1 adipocytes and L6 muscle cells. We determined the
ability of ROK inhibitor (Y-27632) to suppress endogenous
ROK activity by measuring MBS phosphorylation in 3T3-L1 ad-
ipocytes. Insulin increased MBS phosphorylation w2-fold in
3T3-L1 adipocytes, and this was blocked by Y-27632 treat-
ment (Figure 2A). Insulin increased glucose transportw11-fold
in 3T3-L1 adipocytes, but insulin-stimulated glucose transport
was decreased by w50% when adipocytes were treated with
the ROK inhibitor (Figure 2B). Similar results were seen in myo-
tubes and isolated soleus muscle (Figure 2B).Figure 2. Effects of ROK inhibitor on insulin-stim-
ulated glucose transport in 3T3-L1 adipocytes, L6
myotubes, and isolated soleus muscle
A) Effects of ROK inhibitor on MBS phosphorylation
in 3T3-L1 adipocytes. 3T3-L1 adipocytes were pre-
treated with ROK inhibitor Y-27632 (10 M) over-
night or with a vehicle. Cells were stimulated with
insulin (100 nM) for 15 min. Cell lysates were sub-
jected to immunoprecipitation with 5 l of a poly-
clonal ROK antibody. The immune pellets were as-
sayed for ROK phosphorylation using MYPT1 as
substrate.
B) Inhibition of insulin-stimulated glucose transport
by a chemical ROK inhibitor in 3T3-L1 adipocytes,
L6 myotubes, and isolated soleus muscle. 3T3-L1
adipocytes and L6 muscle cells were pretreated
with ROK inhibitor Y-27632 (10 or 30 M) overnight
or with a vehicle. Cells were stimulated with insulin
(100 nM) for 30 min. Isolated soleus muscles from
mice were pretreated with ROK inhibitor Y-27632
(100 M) or with a vehicle for 1 hr and then stim-
ulated with insulin (33 nM) for 30 min. [3H]-2-deoxy-
D-glucose uptake was measured. Data are mean ±
SEM and are representative of three independent
experiments. *p < 0.01 versus the corresponding
condition without inhibitors.CELL METABOLISM : AUGUST 2005Role of ROK in insulin signaling
To determine the mechanism by which ROK regulates insulin-
stimulated glucose uptake, we examined the effects of ROK
inhibition on components of the insulin signaling pathway. In
control adipocytes and myotubes, insulin significantly stim-
ulated IRS-1-associated PI3K activity (9- to 14-fold), and cells
transduced with β-Gal adenovirus yielded similar results. Ex-
pression of DN-ROK resulted in an w50% decrease in insulin-
stimulated PI3K activity in adipocytes and myotubes (Figure
3A). Similarly, insulin-stimulated IRS-1-associated PI3K activity
in isolated soleus muscle was also reduced by treatment with
ROK inhibitor (Figure S1 available with this article online). Insu-
lin increased Akt1 (w15-fold) and Akt2 (w2-fold) activity in
nontransduced 3T3-L1 adipocytes. Interestingly, neither β-Gal
nor DN-ROK expression affected either basal or insulin-stim-
ulated Akt1 and Akt2 activity (Figure 3B). These data indicate
that maximal stimulation of Akt may not require the full activa-
tion of PI3K activity.
Insulin increased PKCλ/ζ activity w2-fold in control 3T3-L1
adipocytes and adipocytes transduced with β-Gal. However,
insulin-induced PKCλ/ζ activity was reduced byw50% in DN-
ROK-expressing adipocytes compared with control cells trans-
duced with β-Gal (Figure 3C). These results suggest that de-
fective activation of atypical PKCλ/ζ in these cells contributes
to decreased glucose uptake and Glut4 translocation, at least
in part.
Neither adenovirus-mediated β-Gal nor DN-ROK expression
had a significant effect on basal or insulin-stimulated tyrosyl
phosphorylation of IR in 3T3-L1 adipocytes (Figure 3D), sug-
gesting that ROK is downstream of IR. However, insulin-stim-
ulated tyrosine phosphorylation of the IRS-1 p85 binding
domain was reduced by w50% in DN-ROK-expressing adipo-
cytes compared with control cells transduced with β-Gal (Fig-121
A R T I C L EFigure 3. Regulation of insulin signaling by ROK in 3T3-L1 adipocytes, L6 myotubes, and CHOIR/IRS-1 cells
A) Effects of DN-ROK on PI3K activity in 3T3-L1 adipocytes and L6 myotubes. Cells were transduced with adenovirus encoding β-Gal or DN-ROK. Cells were stimulated
with insulin (100 nM) for 15 min. Cell lysates were subjected to immunoprecipitation with an IRS-1 antibody. PI3K activity was measured and quantitated using
a phosphorimager.
B) Effects of DN-ROK on Akt isoforms activity in 3T3-L1 adipocytes. 3T3-L1 adipocytes were transduced with adenovirus encoding β-Gal or DN-ROK. Cells were
stimulated with insulin (100 nM) for 15 min. Cell lysates were subjected to immunoprecipitation with antibodies specific for Akt1 or Akt2. The immune pellets were
assayed for kinase activity using Crosstide as substrate.
C) Effects of DN-ROK on PKCλ/ζ activity in 3T3-L1 adipocytes. 3T3-L1 adipocytes were transduced with adenovirus encoding β-Gal or DN-ROK. Cells were stimulated
with insulin (100 nM) for 15 min. Cell lysates were subjected to immunoprecipitation with a PKCλ/ζ antibody. The immune pellets were assayed for kinase activity using
PKC epsilon as substrate.
D) Effects of ROK inhibition on IR tyrosine phosphorylation and IRS-1 p85 binding motif tyrosine phosphorylation in 3T3-L1 adipocytes. IR and IRS-1 were visualized
by immunoblotting with a phosphotyrosine antibody or a phosphotyrosine IRS-1 p85 binding motif antibody. The bands are quantitated using densitometry.
E) Effects of ROK inhibition on IRS-1 binding to the p85 subunit of PI3K in 3T3-L1 adipocytes. Cells lysates were subjected to immunoprecipitation with an IRS-1
antibody. p85 and IRS-1 were visualized by immunoblotting with a p85 antibody or an IRS-1 antibody.
F) ROK inhibition has no effects on Akt, p70S6K, GSK3, and MAPK phosphorylation in 3T3-L1 adipocytes. Akt, p70S6K, GSK3, and MAPK were visualized by
immunoblotting with phospho-specific antibodies.
G) Role of ROK in insulin signaling in CHOIR/IRS-1 cells. CHOIR/IRS-1 cells were transfected with a wt-ROK or a DN-ROK cDNA. After 48 hr, cells were stimulated with
insulin (100 nM) for 15 min. Cell lysates were subjected to immunoprecipitation with an IRS-1 antibody. p85, IR, and IRS-1 were visualized by immunoblotting with a
p85 antibody or a phosphotyrosine, a phospho-specific IRS-1, or a total IRS-1 antibody. The bands are quantitated using densitometry. Data are mean ± SEM and are
representative of three independent experiments. #p < 0.01 versus no virus or β-Gal with insulin. +p < 0.05 versus control. *p < 0.01 versus control. §p < 0.05 versus
wt-ROK.ure 3D). Concurrently, DN-ROK expression also decreased in-
sulin-stimulated binding of IRS-1 to the p85 subunit of PI3K by
w50% in these cells (Figure 3E). These data suggest that ROK
plays an important role in regulating IRS-1 function during insu-
lin stimulation.
DN-ROK had no effect on insulin-stimulated Akt, p70S6K,122GSK3, and MAPK activation (Figure 3F). The protein levels of
IR, p85, p110, and Glut4 were unaltered by DN-ROK (data not
shown). To further elucidate the effects of ROK on insulin sig-
naling, we transfected wild-type (wt) ROK or DN-ROK in
CHOIR/IRS-1 cells. Neither wt-ROK nor DN-ROK expression af-
fected the tyrosine phosphorylation of IR (Figure 3G). Expres-CELL METABOLISM : AUGUST 2005
Rho-kinase as a positive mediator of insulin actionsion of wt-ROK in CHOIR/IRS-1 cells increased insulin-stim-
ulated IRS-1 binding to the p85 subunit of PI3K and IRS-1
tyrosine phosphorylation, but these effects were blocked by
the expression of DN-ROK (Figure 3G). These data indicate
that increased ROK expression is sufficient to enhance insulin
signaling.
ROK directly phosphorylates serine residues
of IRS-1 at 632/635
Until now, it was unknown whether ROK could phosphorylate
IRS-1 directly. To address this issue, we incubated rat recombi-
nant IRS-1 protein with ROK protein in vitro. Strikingly, ROK
increased IRS-1 serine/threonine phosphorylation in vitro, and
this effect was blocked by a ROK inhibitor (Figure 4A). To iden-
tify the serine/threonine phosphorylation sites in IRS-1, we fur-
ther analyzed the phosphorylated IRS-1 protein by mass spec-
trometry. We discovered three serine phosphorylation sites in
IRS-1: Ser632/635, Ser936, and Ser972 from phosphorylated
peptides KGNGDYMPMSPKSVSAPQQIINPIR (molecular mass
of 2807.24 atomic mass units [a.m.u] corresponding to that
predicted for the tryptic peptide encompassing residues 623–
647 [amino acid sequence of rat IRS-1]), EETGSEEYMNM
DLGPGR (molecular mass of 1994.98 a.m.u corresponding to
that predicted for the tryptic peptide encompassing residues
932–948), and VGPAPPGAASICRPTR (molecular mass of
1766.87 a.m.u corresponding to that predicted for the tryptic
peptide encompassing residues 963–978), respectively. These
sites were not phosphorylated by treatment with the ROK in-
hibitor, indicating the specificity of ROK for these three serine
sites (Figure 4A).
To confirm whether ROK phosphorylates IRS-1 in vivo, we
transiently transfected wt-ROK or DN-ROK into CHOIR/IRS-1
cells and labeled the cells with 32P-orthophosphate. Expres-
sion of wt-ROK in CHOIR/IRS-1 cells significantly increased
IRS-1 serine phosphorylation, but these effects were inhibited
by the expression of DN-ROK (Figure 4B). These data indicate
that ROK phosphorylates IRS-1 in vivo, supporting the hypoth-
esis that ROK’s effects on insulin signaling may be mediated
via IRS-1 serine phosphorylation.
We next measured the ability of insulin to activate Ser632/
635 phosphorylation of IRS-1 in adipocytes transduced with
DN-ROK. Insulin significantly increased Ser632/635 phosphor-
ylation of IRS-1 in control adipocytes and adipocytes trans-
duced with β-Gal. In contrast, DN-ROK decreased serine
phosphorylation of IRS-1 at Ser632/635 but not at Ser307 in
adipocytes (Figure 5A). Quantitation from the multiple blots
showed that insulin-induced IRS-1 Ser632/635 phosphoryla-
tion was impaired by w50% in these cells (Figure S2). Consis-
tent with these findings, siRNA-mediated ROK depletion also
significantly reduced insulin-stimulated IRS-1 Ser632/635 phos-
phorylation in 3T3-L1 adipocytes (Figure 5C). Treatment of 3T3-
L1 adipocytes with a chemical ROK inhibitor also decreased
insulin stimulation of IRS-1 Ser632/635 phosphorylation (Fig-
ure 5D). Similarly, expression of wt-ROK increased IRS-1
Ser632/635 phosphorylation, but these effects were blocked
by expression of DN-ROK in CHOIR cells (Figure 5B). These
data suggest that ROK activation is required for Ser632/635
phosphorylation of IRS-1 in these cells.
It has been demonstrated that IRS-1 Ser632/635 phosphory-
lation is also regulated via an mTOR-p70S6K-dependent path-
way. We therefore investigated the effects of this pathwayCELL METABOLISM : AUGUST 2005Figure 4. ROK phosphorylates IRS-1 serine/threonine residues
A) Phosphorylation of IRS-1 by ROK in vitro. Rat recombinant IRS-1 protein
(5 g) was incubated with rat recombinant ROK (1 unit) in the presence of 10
Ci [γ-32P] ATP with or without ROK inhibitor (30 M, Y-27632) for 1 hr at 30°C.
Phosphorylated serine residues in IRS-1 protein were identified by MALDI-TOF
and tandem mass spectrometry.
B) Phosphorylation of IRS-1 by ROK in vivo. CHOIR/IRS-1 cells were transfected
with wt-ROK or DN-ROK cDNA. After 48 hr, cells were incubated with 1 mCi/ml
32P-orthophosphate for 2 hr. Cell lysates were subjected to immunoprecipitation
with 5 l of a polyclonal IRS-1 antibody. Immunoprecipitates were separated by
SDS-PAGE. The gel was dried and exposed to film. The bands were quantitated
using a phosphorimager. Data are mean ± SEM and are representative of two
independent experiments. §p < 0.05 versus wt-ROK.on IRS-1 Ser632/635 phosphorylation in 3T3-L1 adipocytes.
Treatment of 3T3-L1 adipocytes with rapamycin completely
abolished insulin-induced p70S6K phosphorylation. However,
insulin stimulation of IRS-1 Ser632/635 phosphorylation was
partially inhibited by treatment with rapamycin (Figure 5E).
These data suggest that inhibition of p70S6K is not sufficient
to suppress insulin-stimulated IRS-1 Ser632/635 phosphoryla-
tion in adipocytes, implying that other kinases are involved in
the modulation of IRS-1 Ser632/635 phosphorylation. Rapa-
mycin has no effects on insulin-stimulated glucose transport in
3T3-L1 adipocytes (Figure S3).
To establish the effects of Ser632/635 on IRS-1 function, we
generated an IRS-1 with a point mutation that replaced
Ser632/635 with alanine. Insulin significantly increased IRS-1
tyrosine and Ser632/635 phosphorylation in CHOIR cells ex-
pressing wt-IRS-1 (Figure 5F). Expression of IRS-1 Ser632/635
to the alanine mutant significantly decreased insulin-stimulated
IRS-1 tyrosine phosphorylation, IRS-1 binding to the p85 sub-
unit of PI3K, and IRS-1-associated PI3K activity without
changes in IR tyrosine phosphorylation (Figure 5F). These data
indicate that Ser632/635 promotes IRS-1 function during insu-
lin stimulation.
Inhibition of ROK causes insulin resistance in vivo
To further evaluate the role of ROK in glucose metabolism
in vivo, we determined the effects of pre-treatment with a ROK123
A R T I C L EFigure 5. Regulation of IRS-1 Ser632/635 phosphorylation by ROK
A) ROK inhibition by DN-ROK decreases IRS-1 Ser632/635 phosphorylation in 3T3-L1 adipocytes and (B) in CHOIR/IRS-1 cells. 3T3-L1 adipocytes were transduced
with recombinant adenovirus encoding β-Gal or DN-ROK. IRS-1 was visualized by immunoblotting with phospho-serine IRS-1 antibodies or a total IRS-1 antibody.
CHOIR/IRS-1 cells were transfected with wt-ROK or DN-ROK cDNA. After 48 hr, cells were stimulated with insulin (10 nM) for 15 min. IRS-1 was visualized by immunoblot-
ting with a phospho-serine IRS-1 antibody or a total IRS-1 antibody.
C) Inhibition of ROK expression by ROK-siRNA decreases IRS-1 Ser632/635 phosphorylation in 3T3-L1 adipocytes. Cells were transfected with siRNAs by electropora-
tion. After 48 hr, cells were stimulated with insulin (100 nM) for 15 min. IRS-1 was visualized by immunoblotting with a phospho-serine IRS-1 antibody or a total
IRS-1 antibody.
D) Effect of ROK inhibitor on insulin-stimulated IRS-1 Ser632/635 phosphorylation in 3T3-L1 adipocytes. 3T3-L1 adipocytes were pretreated with ROK inhibitor
Y-27632 (100 M) overnight or with a vehicle. Cells were stimulated with insulin (100 nM) for 15 min. IRS-1 was visualized by immunoblotting with a phospho-serine
IRS-1 antibody or a total IRS-1 antibody.
E) Effect of rapamycin on insulin-stimulated IRS-1 Ser632/635 phosphorylation in 3T3-L1 adipocytes. 3T3-L1 adipocytes were pretreated with rapamycin (5 nM) for 1
hr and then stimulated insulin (100 nM) for 15 min. IRS-1 and p70S6K were visualized by immunoblotting with phospho-specific antibodies or a total IRS-1 antibody.
F) Mutation of IRS-1 Ser632/635 to alanine reduces insulin-induced IRS-1 tyrosine phosphorylation and p85 binding to IRS-1. CHOIR cells were transfected with a wt-
IRS-1 or a Ser632/635A-IRS-1 cDNA. After 48 hr, cells were stimulated with insulin (10 nM) for 15 min. Cell lysates were subjected to immunoprecipitation with an
IRS-1 antibody. p85 and IRS-1 were visualized by immunoblotting with a p85 antibody or an IRS-1 antibody. IRS-1 and IR were visualized by immunoblotting with a
phosphotyrosine, a phospho-specific IRS-1, or a total IRS-1 antibody. The bands are quantitated using densitometry. PI3K activity associated with IRS-1 was measured
and quantitated using a phosphorimager. Data are mean ± SEM and are representative of three independent experiments. §p < 0.05 versus wt-ROK.inhibitor (Y-27632) on insulin action during a 2 hr hyperinsulin-
emic-euglycemic clamp in C57BL/6 mice. Plasma insulin levels
were similar between control and Y-27632-treated mice (basal
[pM]: control, 48.7 ± 10.9 versus Y-27632, 47.1 ± 2.2; clamp
[pM]: control, 192.8 ± 17.4 versus Y-27632, 181.2 ± 20.3). Pre-
treatment with Y-27632 caused whole-body insulin resistance,
with a 32% decrease in the glucose infusion rate as compared
to the control mice (Figure 6A). This was mostly due to w40%
decreases in insulin-stimulated whole-body glucose turnover
and skeletal muscle glucose uptake in mice treated with
Y-27632 (Figures 6B and 6C). In contrast, insulin-mediated
suppression of HGP (i.e., hepatic insulin action) was unaltered
by treatment with the ROK inhibitor at the employed insulin
clamp dose (Figure 6D). Insulin-stimulated whole-body glycoly-
sis and glycogen synthesis were also reduced by ROK inhibi-
tion (data not shown). These results demonstrate that inhibition
of ROK causes insulin resistance in skeletal muscle and further
implicate ROK as an important regulator of glucose homeosta-
sis in vivo.
Insulin activates the Rho/ROK pathway in skeletal
muscle in vivo
To determine the ability of insulin to increase Rho activity
in vivo, we measured GTP-Rho activity using the Rho binding124domain of rhoteckin in skeletal muscle. Consistent with the
previous findings (Karnam et al., 1997), insulin significantly in-
creased GTP-Rho activation w3.6-fold in skeletal muscle in
vivo (Figure 7A). Next, we determined the specificity of S6 ki-
nase substrate for ROK activity by measuring ROK activity with
or without Y-27632 inhibitor in skeletal muscle of normal mice.
Basal ROK activity was decreased by w50% when IRS-1 im-
munoprecipitates were incubated with ROK inhibitor Y-27632.
Insulin increased ROK activity w1.7-fold, but this effect was
inhibited by treatment with ROK inhibitor in the muscle of nor-
mal mice (Figure 7B). These data suggest that S6 kinase sub-
strate is specific for ROK activity.
Discussion
A key action of insulin is to stimulate glucose transport into
cells by inducing the translocation of Glut4 from intracellular
storage sites to the plasma membrane (Minokoshi et al., 2003).
In the insulin signaling pathway, tyrosine phosphorylation of
IRS-1 is an important step because it permits this docking pro-
tein to interact with signaling proteins that promote insulin ac-
tion (White, 2002). ROK, a downstream target for Rho, has
been shown to participate in the insulin signaling network byCELL METABOLISM : AUGUST 2005
Rho-kinase as a positive mediator of insulin actioninteracting with IRS-1 (Begum et al., 2002; Farah et al., 1998).
Therefore, it is of great interest to identify the role of ROK in
IRS-1-mediated insulin signaling and glucose metabolism. We
have shown that ROK activation is required for insulin-stim-
ulated glucose transport in adipocytes, muscle cells, and iso-
lated soleus muscle ex vivo. This effect is mediated through
PI3K activation, which can be positively regulated by serine
phosphorylation of IRS-1. Thus, ROK is an important mediator
of insulin signaling and glucose metabolism.
In this study, we determined that ROK can regulate insulin-
stimulated glucose transport. We show herein that adenovirus-
mediated expression of DN-ROK significantly decreases insu-
lin-stimulated glucose uptake in adipocytes and myotubes.
Consistent with these results, insulin stimulation of glucose up-
take is also impaired when ROK is inactivated by a chemical
inhibitor in these cells and in isolated soleus muscle ex vivo.
These data are further supported by the fact that the infusion
of a ROK inhibitor causes insulin resistance by reducing whole-
body and muscle glucose uptake in mice in vivo. Together,
these data strongly suggest that ROK regulates insulin-stim-
ulated glucose transport in adipocytes and muscle cells as well
as in the whole body in vivo.
Insulin signaling involves a cascade of events initiated by
insulin binding to its cell-surface receptor, followed by activa-
tion of the receptor tyrosine kinase, which results in the tyro-Figure 6. In vivo role of ROK in glucose metabolism
Mice were infused with saline or ROK inhibitor Y-27632 (0.25 mg/hr) for 2 hr
followed by a 2 hr hyperinsulinemic-euglycemic clamp (2.5 mU/kg/min). After
clamps, gastrocnemius muscle was rapidly removed and analyzed. (A) Glucose
infusion rate, (B) insulin-stimulated whole-body glucose turnover, (C) insulin-stim-
ulated skeletal muscle glucose uptake, (D) basal and insulin-stimulated hepatic
glucose production. Data are means ± SEM for 6–8 mice. +p < 0.05, #p < 0.01
versus control.CELL METABOLISM : AUGUST 2005sine phosphorylation of IRS-1. Binding of IRS-1 to the p85 reg-
ulatory subunit of PI3K via YXXM domains results in the
activation of PI3K, which is necessary for insulin action on glu-
cose transport (White, 2002). Here we show that inhibition of
ROK decreases insulin-stimulated IRS-1-associated PI3K ac-
tivity in adipocytes and myotubes. This is mainly due to de-
creased tyrosine phosphorylation of the YXXM motif in IRS-1,
which can lead to reduced interaction of IRS-1 with the p85
subunit of PI3K. Indeed, insulin-stimulated IRS-1 binding to the
p85 regulatory subunit of PI3K is impaired in adipocytes ex-
pressing DN-ROK. This is further confirmed by transfection
studies in CHO cells. Therefore, it seems likely that the mecha-
nism for the impairment of glucose transport by ROK inactiva-
tion involves a major defect in the activity of PI3K, which can
be regulated by the interaction of IRS-1 with the p85 subunit
of PI3K.
Interestingly, we found that insulin-stimulated PI3K and
PKCλ/ζ activities are significantly reduced in adipocytes ex-
pressing DN-ROK, whereas another PI3K target Akt is not af-
fected at all. Consistent with our results, several studies in in-
sulin-resistant rodent models including GK diabetic rats (Kanoh
et al., 2000), PTP-1B transgenic mice (Zabolotny et al., 2004),
and FFA-infused rats (Kim et al., 2002) and in obese diabetic
monkeys (Standaert et al., 2002) also show decreased insulin-
stimulated PKCλ/ζ activity in skeletal muscle. Thus, these data
suggest that reduced insulin-stimulated atypical PKC activity
in adipocytes contributes to the decreased glucose uptake
and metabolism.
Previous studies indicate that the activation of Rho can im-
pair the early steps of insulin/IGF signaling, including IRS-1 ty-
rosine phosphorylation in vascular smooth muscle cells (Be-
gum et al., 2002) and fibroblasts derived from p190B RhoGAP
null mice (Sordella et al., 2002). In this regard, it seems unlikely
that the alteration in the Rho signaling can simply explain all
aspects of its downstream pathways. Since Rho has multiple
target molecules including rhophilin, rhotekin, citron, and pro-
tein kinase N (Madaule et al., 1998; Reid et al., 1996; Shibata
et al., 1996; Watanabe et al., 1996), it is unclear whether an
inhibitory role of Rho on insulin signaling occurs through ROK
or other downstream mediators. In fact, insulin activates MAPK
through a ROK pathway that is independent of Rho signaling
pathway (Ohan et al., 1999).
We propose the potential mechanism by which ROK regu-
lates IRS-1 function, which can modulate the interaction of
IRS-1 with the p85 subunit of PI3K (Figure 7C). Our data dem-
onstrate that ROK directly phosphorylates serine/threonine
residues on IRS-1 protein in vitro, but this effect is completely
abolished by treatment with a ROK inhibitor, indicating that this
effect is specific for ROK. This is further confirmed by in vivo
studies in CHO cells. By mass spectrometry analysis, we iden-
tified the serine residues of IRS-1 at Ser632/635, Ser936, and
Ser972, which are phosphorylated by ROK. As expected, ex-
pression of DN-ROK decreases serine phosphorylation of
IRS-1 at Ser632/635 in adipocytes. Support for ROK’s effect
on IRS-1 serine phosphorylation comes from transfection
studies showing that wt-ROK expression in CHO cells express-
ing IR and IRS-1 increases Ser632/635 phosphorylation of
IRS-1, whereas expression of DN-ROK inhibits this phosphory-
lation. Given that Ser632/635 residue is adjacent to the YXXM
motif domain in IRS-1 (White, 2002), it is conceivable that the
reduction in serine phosphorylation of IRS-1 could inhibit a125
A R T I C L Econformational change in the phosphotyrosine binding domain
that enhances its affinity for PI3K. As a result, the ability of
IRS-1 to bind to the p85 subunit is diminished, leading to re-
duced PI3K activity.
We further characterized the functional role of Ser632/635
sites in IRS-1 by mutating these sites. Replacing serine 632/
635 with alanine causes a significant inhibition of insulin-stim-
ulated tyrosine phosphorylation of IRS-1 and binding of IRS-1
to the p85 subunit of PI3K. We thus hypothesized that Ser632/
635 phosphorylation positively regulates insulin action by facili-
tating the interaction of IRS-1 with the p85 subunit. However,
some studies indicate that Ser632/635 phosphorylation of
IRS-1 is involved in the negative regulation of insulin signaling
(Ozes et al., 2001; Um et al., 2004). It has been reported that
mTOR phosphorylates these residues and reduces IRS-1 tyro-
sine phosphorylation, thereby inhibiting insulin signaling (Ozes
et al., 2001). A possible explanation for this discrepancy is that
these sites in IRS-1 could have a dual role in serving as either aFigure 7. Effects of insulin on the Rho/ROK path-
way in skeletal muscle
A) Insulin stimulates GTP bound Rho activation in
skeletal muscle from normal mice. Mice were fasted
for 18 hr, injected intravenously with saline or insulin
(10 U/kg), and killed 15 min post-injection. Muscle
lysates were incubated with recombinant Rhotekin
(Rho binding domain) protein. Rho was visualized
by immunoblotting with a Rho antibody. The bands
are quantitated using densitometry.
B) Specificity of S6 kinase substrate for ROK activ-
ity. Muscle lysates were subjected to immunopreci-
pitation with an IRS-1 antibody. ROK activity was
measured with or without ROK inhibitor Y-27632 (10
M) using long S6 kinase peptide as a substrate.
Data are means ± SEM for 4–6 mice. *p < 0.01 ver-
sus control. ‡p < 0.05 versus the corresponding
condition without inhibitors. +p < 0.05 versus saline-
injected control.
C) A potential mechanism by which ROK regulates
insulin-mediated signaling and glucose metabolism.126positive or negative modulator of insulin signaling under certain
conditions. In fact, phosphorylation of Ser789 in IRS-1 can en-
hance insulin signaling in AICAR-treated myotubes (Jakobsen
et al., 2001) while it also attenuates insulin signaling in liver of
insulin-resistant animals (Qiao et al., 2002).
Based on our studies, we propose a hypothesis for the in-
volvement of ROK in insulin signaling and glucose metabolism.
Upon insulin stimulation, ROK is activated and rapidly phos-
phorylates IRS-1 on serine residues, which in turn increases
the ability of IRS-1 to activate PI3K, leading to enhanced glu-
cose transport activity and other downstream pathways.
Therefore, we suggest that ROK is a positive regulator of insu-
lin action and glucose metabolism. This model provides a new
mechanism for understanding insulin action and insulin resis-
tance. Finally, these findings raise the possibility that the devel-
opment of small molecule activators for ROK could offer a
novel target for the treatment of type 2 diabetes mellitus.CELL METABOLISM : AUGUST 2005
Rho-kinase as a positive mediator of insulin actionExperimental procedures
Cell Culture for 3T3-L1 adipocytes, L6 myotubes,
CHO cells, and 293 cells
3T3-L1 cells were grown and differentiated as described (Huppertz et al.,
2001). Cells were used for experiments 10–12 days after the induction of
differentiation. L6 muscle cells (a gift from Amira Klip, Toronto, Canada)
were grown and differentiated as described (Huppertz et al., 2001). These
cells were used for experiments 4–6 days after induction of differentiation.
CHO cells expressing IR and IRS-1 (CHOIR/IRS-1) and expressing IR (CHOIR)
were grown as described (Myers et al., 1998).
Transduction of 3T3-L1 adipocytes and L6 myotubes
Transduction of differentiated 3T3-L1 adipocytes and L6 myotubes was per-
formed as described (Huppertz et al., 2001). Dominant-negative ROK (DN-
ROK) α (Morishige et al., 2001) or β-galactosidase (β-Gal) encoding recom-
binant adenoviruses were used at a concentration of 1 × 108 PFU/ml (as
determined by limiting dilution) for L6 myotubes and 1 × 109 PFU/ml for
3T3-L1 adipocytes. The virus was removed after a 14 hr exposure, and
experiments were performed following an additional 48 hr incubation in
fresh media.
Transfection of CHO cells
CHOIR/IRS-1 cells were transfected with wt-ROK or DN-ROK cDNA as de-
scribed (Myers et al., 1998). CHOIR cells were transfected with wt-IRS-1 or
Ser632/635A-IRS-1 (mutant IRS-1 protein containing an alanine substitu-
tion for Ser632/635) cDNA as described (Myers et al., 1998). Transfected
cells were incubated overnight. After 24 hr, cells were starved overnight and
stimulated with insulin (100 nM) for 15 min.
Glucose transport and Glut4 translocation
3T3-L1 adipocytes and L6 myotubes were transduced with recombinant
adenovirus encoding DN-ROK or β-Gal adenoviruses as described above.
Cells were starved and stimulated with insulin (100 nM) for 30 min. [3H]-2-
deoxy-D-glucose was measured as described (Huppertz et al., 2001), and
the results are expressed as a percentage of basal glucose transport in
control cells. 3T3-L1 adipocytes and L6 myotubes were pretreated with
ROK inhibitor Y-27632 (10–30 M, Calbiochem, La Jolla, California) or with
a vehicle overnight. Cells were starved and stimulated with insulin (100 nM)
for 30 min. Isolated soleus muscle from FVB mice was pretreated with ROK
inhibitor Y-27632 (100 M) or with vehicle for 2 hr and stimulated with insu-
lin (33 nM) for 30 min. Y-27632 is a highly specific potent, cell-permeable,
selective inhibitor of ROK. Inhibition is achieved by competing with ATP for
binding to the catalytic site (Uehata et al., 1997). For Glut4 translocation,
3T3-L1 adipocytes overexpressing Glut4 (a gift from Kazuhiro Kishi, Univer-
sity of Tokushima, Japan) (Katome et al., 2003) were transduced with re-
combinant adenovirus encoding DN-ROK or β-Gal adenoviruses. Cell-sur-
face bound myc-GLUT4 was detected using a myc-tag antibody as
described (Wang et al., 1998).
Design and synthesis of small interfering RNA (siRNA)
The murine ROK α sequence 5#-CAAUGAAGCUUCUUAGUAA-3# was tar-
geted for RNA interference. The siRNA double-stranded oligonucleotides
were synthesized in the 2#-ACE(TM) protected form, which enhances over-
all RNA stability and resistance to nucleases (Dharmacon, Lafayette, Colo-
rado). The control nontargeting siRNA (D-001206-13-20) was purchased
from Dahmarcon Inc.
Electroporation of 3T3-L1 adipocytes
3T3-L1 adipocytes were transfected with siRNA oligonucleotides by
electroporation as described (Jiang et al., 2003). The adipocytes at day 4
of differentiation were detached from culture dishes with 0.05% trypsin and
1.0 mg of collagenase/ml in PBS, washed twice, and resuspended in PBS.
Approximately 5 million cells were then mixed with siRNA duplexes, which
were delivered to the cells by a pulse of electroporation with a Bio-Rad
gene pulser II system at the setting of 0.18 kV and 950 µF capacitance.
After electroporation, cells were immediately mixed with fresh medium and
plated. After 48 hr, cells were used for the glucose uptake and signaling
analysis.CELL METABOLISM : AUGUST 2005Determination of PI3K, Akt, and PKCλ/ζ activity
Cell lysates (100 g protein) were subjected to immunoprecipitation for 4
hr at 4°C with 5 l of a polyclonal IRS-1 antibody (a gift from Dr. Morris
White, Joslin Diabetes Center), 5 l of a polyclonal Akt1 (a gift from Thomas
Franke, Columbia University), 5 l of Akt2 (a gift from Thomas Franke, Co-
lumbia University), or 5 l of a polyclonal PKCζ antibody (Santa Cruz Bio-
technology; Santa Cruz, California), coupled to protein A-sepharose beads
(Sigma; St. Louis, Missouri). The immune complex was washed, and PI3K,
Akt, and PKCλ/ζ activity were determined as described (Kim et al., 2002).
Immunoblotting and immunoprecipitation
3T3-L1 adipocytes were starved and stimulated with insulin (100 nM) for 15
min. For interaction between p85 and IRS-1, cell lysates (100 g protein)
were subjected to immunoprecipitation with 5 l of a polyclonal IRS-1 anti-
body coupled to the protein A-sepharose (Sigma). Association of p85 with
IRS-1 was determined as described (Zabolotny et al., 2001). For association
between ROK and IRS-1, muscle lysates (500 g protein) were subjected
to immunoprecipitation with 2 g of a polyclonal ROK antibody (Santa Cruz
Biotechnology) coupled to protein G-sepharose (Pharmacia Biotechnology;
Piscataway, New Jersey). Immunoprecipitates were washed and separated
by SDS-PAGE and transferred to nitrocellulose membranes. The mem-
branes were incubated with a polyclonal IRS-1 antibody. Cell lysates (10–
30 g protein) or tissue lysates (50 g protein) were resolved by SDS-PAGE
and transferred to nitrocellulose membranes. The membranes were incu-
bated with antibodies against a monoclonal phosphotyrosine antibody
(Santa Cruz Biotechnology); a polyclonal p85 PI3K binding motif antibody
(Cell Signaling; Beverly, Massachusetts); a polyclonal phospho-Ser632/
635IRS-1 (Cell Signaling); a polyclonal phospho-Ser307IRS-1 (Upstate Bio-
technology); a polyclonal phospho-Ser473Akt (Cell Signaling); a polyclonal
phospho-Thr308Akt (Cell Signaling); a polyclonal phospho-Ser21/9GSK3
(Cell Signaling); a polyclonal phospho-The38970S6 kinase (Cell Signaling);
a polyclonal phospho (pTEpY) MAPK antibody (Promega; Madison, Wis-
consin); a polyclonal ROK α antibody (Santa Cruz); or a monoclonal myc
tag antibody (Upstate Biotechnology). The bands were visualized with en-
hanced chemiluminescence and quantified by densitometry.
Phosphorylation of myosin binding subunit (MBS/MYPT1)
3T3-L1 adipocytes were pretreated with ROK inhibitor Y-27632 (10 M) or
with a vehicle overnight. The cells were starved and stimulated with insulin
(100 nM) for 15 min. Cell lysates (100 g protein) were subjected to immu-
noprecipitation for 4 hr with 10 l of a polyclonal ROK antibody, coupled to
protein G-sepharose beads (Pharmacia Biotechnology). Immune pellets
were washed and resuspended in a 50 l of kinase mixture (20 mM Tris,
pH 7.5, 5 mM MgCl2, 100 mM KCl, 0.1 mM DTT, 100 M ATP, 1 mM EDTA,
1 M microcystin-LR, 1 g MYPT1 substrate protein [Upstate Biotechnol-
ogy], and 1 Ci [γ-32P] ATP) and incubated at 30°C for 30 min. Immunopre-
cipitates were separated by SDS-PAGE. The gel was dried and exposed
to film.
Phosphorylation in vitro
Rat recombinant IRS-1 protein (Upstate Biotechnology) was incubated with
rat recombinant ROK (Upstate Biotechnology). The reactions were carried
out on 5 g of IRS-1 with 1 unit of ROK protein in a 30 l phosphorylation
buffer (50 mM Tris pH 7.4, 100 mM MgCl2, 10 mM DTT, 50 M ATP, and 10
Ci [γ-32P] ATP) with or without a ROK inhibitor (30 M, Y-27632) for 1 hr
at 30°C. Proteins were separated by SDS-PAGE. The gel was dried and
exposed to film. One unit of ROK activity is defined as 1 nmol phosphate
incorporated into substrate per minute at 30°C. ROK phosphorylated
IRS-1 in the presence of ATP to a level approaching 0.67 moles of incorpo-
rated phosphate per moles of IRS-1 protein.
Phosphorylation in vivo
CHOIR/IRS-1 cells were transfected with wt- or DN-ROK cDNA as described
(Myers et al., 1998). Cells were phosphate-free starved for 1 hr and then
labeled for 2 hr with 1 mCi/ml 32P-orthophosphate. Cell lysates were sub-
jected to immunoprecipitation with 5 l of a polyclonal IRS-1 antibody cou-
pled to protein A-sepharose. Immunoprecipitates were separated by SDS-
PAGE. The gel was dried and exposed to film.127
A R T I C L EMass spectrometry analysis
Mass spectrometry analysis of the phosphorylated IRS-1 by Rho-kinase
was followed as described (Xue et al., 2004). Briefly, the phosphorylated
IRS-1 band was reduced and alkylated by DTT and iodoacetamide, respec-
tively. After gel dehydration in acetonitrile, trypsin digestion was performed
overnight at 37°C. Phosphorylated peptides of IRS-1 were analyzed by
MALDI-TOF mass spectrometry (Voyager-DESTR, Applied Biosystems)
using α-Cyano-4-hydorxycinnamic acid as matrix. In the reflector mode,
20000V of accelerating voltage and 200 ns of extraction delay time were
applied. The acquisition mass range was 750–4500 Da with a 600 Da low
mass gate. One trypsin peptide (MW = 842.5099) was used as the internal
mass standard.
Mutagenesis
IRS-1 double-point mutant for Ser632/635 to alanine (Ser632/635A) was
generated using the PCR-based megaprimer method (Sarkar and Sommer,
1990). The mutagenic primer for the Ser632/635A (5#-CTGCTGGGGGGCA
GATACAGCCTTGGGGGCCATGGGCATATAGTCCCC-3#) and a reverse
primer (5#-TACCCACCAGGAGGTGGCAGTGGA-3#) were used. PCR was
performed as described (Sarkar and Sommer, 1990). The mutation was con-
firmed by restriction digestion and by dideoxynucleotide sequence analysis.
Hyperinsulinemic-euglycemic clamps
After an overnight fast, male C57BL/6 mice were infused with saline or ROK
inhibitor Y-27632 (0.25 mg/hr) for 2 hr, and a 2 hr hyperinsulinemic (2.5 mU/
kg/min)-euglycemic clamp was performed in awake mice as described (Kim
et al., 2004). Briefly, basal and insulin-stimulated whole-body glucose turn-
over were estimated with a continuous infusion of [3-3H] glucose during
clamps, and 2-deoxy-D-[1-14C]glucose (2-[14C]DG; NEN) was administered
as a bolus to assess insulin-stimulated glucose uptake in skeletal muscle.
Rates of basal hepatic glucose production (HGP) and insulin-stimulated
whole-body glucose turnover were determined as described (Kim et al.,
2004). Muscle glucose uptake was measured as described (Kim et al.,
2004). All procedures were approved by the Yale University Animal Care
and Use Committee.
Rho pull-down assay and ROK activity
Male FVB mice (8 weeks of age) were fasted overnight. A bolus injection of
insulin (10 U/kg) was administered through the tail vein. Fifteen minutes
later, gastrocnemius was rapidly removed and lysed as described (Kim et
al., 2002). Muscle lysates (500 g protein) were incubated with 25 g of
recombinant Rhotekin protein (Rho binding domain, Upstate Biotechnology)
bound to glutathione-agarose for 1 hr at 4°C. The agarose beads were
washed and subjected to immunoblotting analysis with a polyclonal Rho
antibody. Muscle lysates (500 g protein) were subjected to immunoprecipi-
tation for 4 hr at 4°C with 5 l of a polyclonal IRS-1 antibody (1:100 dilution),
coupled to protein A-sepharose beads. Immune pellets were washed and
resuspended in 50 l of kinase mixture (20 mM Tris, pH 7.5, 5 mM MgCl2,
100 mM KCl, 0.1 mM DTT, 1 mM EDTA, 100 M ATP, 1 M microcystin-
LR, 40 M long S6 kinase substrate peptide [Upstate Biotechnology], and
1 Ci [γ-32P] ATP) and incubated at 30°C for 30 min. Forty microliters of
samples were spotted onto phosphocellulose p81 paper (Whatman; Clifton,
New Jersey) and washed. Radioactivity of the p81 paper was determined
by scintillation counting.
Statistical analysis
Data are presented as mean ± SEM. Statistical analyses were performed
using Stat View (Abacus Concepts, Inc.; Berkeley, California). Statistical sig-
nificance among the groups was tested with analysis of variance (ANOVA)
and unpaired Student’s t test when appropriate.
Supplemental data
Supplemental data include three figures and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/2/2/119/DC1/.
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